The Pulse of the MedTech Industry Report 2024 from EY is now available for download! While research shows that the MedTech industry is still growing, it is increasingly walking a narrow path between converging top-line and bottom-line pressures. With deep insights from EY thought leaders and perspectives from top MedTech executives on the current financing environment, capital efficiency viewpoints, what’s next in MedTech financing, and the future of innovation, the EY analysis on the state of the industry leaves no stone unturned.
Click here for details: www.ey.com/pulse
Related Reading
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
The Kennedy v Braidwood Ruling: What’s Next for MedTech
July 17, 2025
2:00 PM – 3:30 PM
Join AdvaMed and Reed Smith experts to explore how the Supreme Court’s ACA ruling in Braidwood could shape preventive care and MedTech policy.
Resource / Coverage & Payment / Emerging Policy Response Resources / Global & Trade / Supply Chain / Tariffs
Supreme Court’s Decision in Kennedy v. Braidwood Management, Inc.
July 2, 2025
Explore the impact of the Supreme Court’s decision in Kennedy v. Braidwood on the ACA preventive services mandate and its implications for MedTech policy.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 6/27
June 30, 2025
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through June 17, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update – 6/20
June 20, 2025
Member-only summary of IEEPA “fentanyl” and reciprocal tariffs under EO 14257, plus status of related legal challenges across federal courts through June 17, 2025.
Resource / Emerging Policy Response Resources / Tariffs
Tariff-related Litigation Update
June 16, 2025
Explore the latest IEEPA tariff developments and legal challenges, including executive orders on fentanyl tariffs and reciprocal duties affecting global MedTech trade.
Blog / Global & Trade / Government & Legislative Affairs / Regulatory Affairs / Tariffs
Medtech is Essential: Industry Supports Call for Tariff Flexibility
May 29, 2025
AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly, the patients who depend on it.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
URGENT: Court Ruling on Tariffs — Implications for Medtech
Now On Demand!
Emergency Briefing on Court Ruling on Tariffs and Its Impact on Medtech. Now On Demand!
News / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Tariffs
Swiss Medtech and AdvaMed Call for Zero for Zero Tariffs and Recognition of FDA Approvals and Clearances
May 20, 2025
Bern/Washington – Swiss Medtech, the leading trade association for medical technology companies in Switzerland, and AdvaMed, the U.S. Medtech Association and the world’s largest organization representing medtech innovators, are jointly calling for reciprocal “zero for zero” tariffs between the two countries.